CLINICAL VALUE OF DETERMINING GALECTIN-3 IN PATIENTS WITH CHRONIC HEART FAILURE

Abstract

Relevance:today, the task of finding new biomarkers that could help monitor the effectiveness of pharmacotherapy, ensuring early diagnosis and predicting the clinical outcome of the disease continues to be relevant.Purpose:the purpose of the study was to assess the clinical value of determining galectin-3 in patients with chronic heart failure (CHF).Material and methods:the study included 53 patients (women n = 31, men n = 22) with CHF II-III FC NYHA. The mean age of patients was 71 (95% CI 68.99-74.37). The group of patients with CHF II NYHA included 14 people, and the group with CHF III NYHA - 39. The median baseline level for NT-proBNP was 65.7 pmol/L, the median baseline for galectin-3 - 8.37 pmol/L.Results:increased levels of galectin-3 correlated with reduced EF (%) (R = -0.26, p = 0.04), increased serum creatinine (r = 0.26, p = 0.04) and elevated plasma levels of NT-proBNP (r = 0.3, p = 0.02). No statistically significant relationship was obtained with other clinical indicators, such as SBP, DBP, heart rate, BMI, the 6-minute test, LVMI, LVM, glucose, TC, GFR. We obtained a moderate correlation between the plasma levels of NT-proBNP and galectin-3 (r = 0.3, p = 0.02). Reduced levels of galectin-3 after treatment were observed in 84.3% of patients.Conclusion.Galectin-3 can be used as an additional diagnostic biomarker for CHF. The incidence of congestive heart failure (CHF) is 1–2% among the population in the developed countries reaching >10% in patients aged over 70 years. [1] Despite a significant progress in the treatment of CHF over the past decades, the mortality rate is very high reaching 60% in men and 45% in women after 5 years after the initial diagnosis. [2] Therefore, the development of new methods for the prevention and treatment of CHF is a relevant medical and social problem.